SCHEMBL3227306

SCHEMBL3227306

CC1=C(C(N)=O)[N]c2ccc(S(C)(=O)=O)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
MAP4K4 O95819 1/20 0.38
IKBKB O14920 2/20 0.37
BRD4 O60885 1/20 0.37
AURKA O14965 1/20 0.36
ROCK2 O75116 1/20 0.36
CHEK2 O96017 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR3 P22607 1/20 0.36
CDK2 P24941 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
MAPK9 P45984 1/20 0.36
CSNK1D P48730 1/20 0.36
GSK3A P49840 1/20 0.36
RPS6KA3 P51812 1/20 0.36
LIMK1 P53667 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CDK5 Q00535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231611 0.77 SLC9A1 (0.38) JAK2JAK1TYK2JAK3
SCHEMBL3233055 0.73 NOTUM (0.41) IKBKBPTGDR2JAK2JAK1TYK2
SCHEMBL3223527 0.72 MAP4K4 (0.39) LMNAMAP4K4IKBKBBRD4AURKA
SCHEMBL4959356 0.69 MAPK1 (0.55) LMNAIKBKBBRD4CHUKG6PD
SCHEMBL28166017 0.69 LMNA (0.46) LMNAIKBKBBRD4CHUKG6PD
SCHEMBL3223520 0.69 LMNA (0.36) LMNAMAP4K4IKBKBAURKAROCK2
SCHEMBL3222455 0.66 MAP4K4 (0.39) LMNAMAP4K4IKBKBAURKAROCK2
SCHEMBL3222450 0.66 LMNA (0.36) LMNAMAP4K4IKBKBAURKAROCK2
SCHEMBL3652331 0.65 G6PD (0.43) LMNAMAP4K4ROCK1G6PDIDE
SCHEMBL1017780 0.64 LMNA (0.61) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 LMNA 3470/4885MAP4K4 2134/4885IKBKB 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.